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HLBACKGROUND In children with single right ventricular (RV) anomalies, changes in RV size and function may
be inﬂuenced by shunt type chosen at the time of the Norwood procedure.
OBJECTIVES The study sought to identify shunt-related differences in echocardiographic ﬁndings at 14 months
and #6 months pre-Fontan in survivors of the Norwood procedure.
METHODS We compared 2-dimensional and Doppler echocardiographic indices of RV size and function, neo-aortic and
tricuspid valve annulus dimensions and function, and aortic size and patency at 14.1  1.2 months and 33.6  9.6 months
in subjects randomized to a Norwood procedure using either the modiﬁed Blalock-Taussig shunt (MBTS) or right ventricle
to pulmonary artery shunt (RVPAS).
RESULTS Acceptable echocardiograms were available at both time points in 240 subjects (114 MBTS, 126 RVPAS). At 14
months, all indices were similar between shunt groups. From the 14-month to pre-Fontan echocardiogram, the MBTS
group had stable indexed RV volumes and ejection fraction, while the RVPAS group had increased RV end-systolic
volume (p ¼ 0.004) and decreased right ventricular ejection fraction (RVEF) (p ¼ 0.004). From 14 months to pre-
Fontan, the treatment groups were similar with respect to decline in indexed neo-aortic valve area, >mild neo-aortic
valve regurgitation (<5% at each time), indexed tricuspid valve area, and $moderate tricuspid valve regurgitation
(<20% at each time).
CONCLUSIONS Initial Norwood shunt type inﬂuences pre-Fontan RV remodeling during the second and third years of
life in survivors with single RV anomalies, with greater RVEF deterioration after RVPAS. Encouragingly, other indices of
RV function remain stable before Fontan regardless of shunt type. (Comparison of Two Types of Shunts in Infants with
Single Ventricle Defect Undergoing Staged Reconstruction—Pediatric Heart Network; NCT00115934) (J Am Coll Cardiol
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2027AB BR E V I A T I O N S
AND ACRONYM S
BSA = body surface area
MBTS = modiﬁed
Blalock-Taussig shunt
MPI = myocardial
performance index
RV = right ventricular
RVEF = right ventricular
ejection fraction
RVPAS = right ventricle-to-
pulmonary artery shunt
SVR = single ventricle
reconstruction
tricuspid valveT he Pediatric Heart Network (1) SVR (SingleVentricle Reconstruction) trial comparedoutcomes in 549 infants undergoing a Nor-
wood procedure for single right ventricle anomalies
randomized to either a modiﬁed Blalock-Taussig
shunt (MBTS) or right ventricle to pulmonary artery
shunt (RVPAS) at 15 North American centers (2). The
trial’s primary ﬁnding was superior 1-year
transplant-free survival in subjects who received a
RVPAS compared with those who had an MBTS (3).
However, initial shunt type for the Norwood proce-
dure did not impact echocardiographic indices
measured after shunt removal (4). Speciﬁcally, at
14 months, right ventricular (RV) systolic, diastolic,
and global function; cardiac and vascular dimen-
sions; neo-aortic and tricuspid annulus dimensions
and valve function; and neo-aortic ﬂow patterns
all were similar for survivors with MBTS or RVPAS.
Although signiﬁcant interstage differences were
noted in neo-aortic annular size and ﬂow patterns
between shunt types before stage II palliation,
these were explained by the differing shunt
physiologies.SEE PAGE 2036On the basis of these results, we hypothesized
that differences in echocardiographic ﬁndings
between the shunt groups would emerge with
longer-term follow-up. RV dysfunction related to
the creation of a right ventriculotomy in the RVPAS
group was of particular concern. The Pediatric Heart
Network’s SVR Extension Study was undertaken to
provide longitudinal surveillance of the cohort,
including echocardiography within 6 months of
Fontan palliation. In this analysis, we compared
2-dimensional (2D) and Doppler indices of RV size
and function, neo-aortic and tricuspid valve (TV)
annulus dimensions and function, and aortic size
and patency to evaluate these changes for the sec-
ond and third years of life for our cohort, picking
up at 14 months when the original analysis left off
and then conducting echocardiographic analysis
again before the Fontan procedure. By investigating
changes over time, we sought to identify echocar-
diographic features at 14 months that predict clin-
ical outcomes.do not necessarily represent the ofﬁcial views of the National Heart, Lung, an
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SUBJECTS. Entry criteria for subjects in the
SVR trial have been reported previously (2).
In the current study, all SVR trial survivors
who underwent a transthoracic echocardio-
gram within 6 months of planned Fontan
palliation and had that study submitted to
the SVR core echocardiography lab for inter-
pretation were eligible for inclusion. We
excluded subjects who underwent biven-
tricular repair (n ¼ 3), had their pre-Fontan
echocardiogram outside the 6-month win-
dow before Fontan surgery (n ¼ 2), or had no
Fontan procedure scheduled at the time of
this data collection (n ¼ 16).
STUDY DESIGN. The SVR study design also has pre-
viously been published (2). Brieﬂy, SVR is a ran-
domized clinical trial of infants with a diagnosis of
single, morphologically right ventricle anomaly un-
dergoing a Norwood procedure. The primary outcome
has been published (incidence of death or cardiac
transplantation at 12 months after randomization)
(3), as have secondary outcomes, including hospital
morbidity and rate of serious adverse events through
12 months, and risk factors for mortality and cardiac
transplantation (5–7). The secondary echocardio-
graphic markers of outcome for the SVR trial pre-
viously reported included 14-month indices of RV
function, cardiac and vascular dimensions, valve
annulus dimensions and function, and neo-aortic
ﬂow patterns (4).
ECHOCARDIOGRAPHIC ANALYSIS. For the SVR
Extension Study, an echocardiography core labora-
tory at the Medical College of Wisconsin reviewed
2D/Doppler echocardiograms performed at each clin-
ical center within 6 months of a planned Fontan pro-
cedure. Core lab procedures for image analysis and
data management have been previously described
(4). Echocardiographic measures obtained from the
imaging are summarized in Tables 1 and 2.
STATISTICAL ANALYSIS. Summary descriptive sta-
tistics of echocardiographic indices are presented by
intended shunt type for the Norwood procedure.
Distributions of echocardiographic indices were
TV =d Blood Institute. Dr. Hill has received grant support
rted that they have no relationships relevant to the
ntin Fuster.
r. Valentin Fuster.
TABLE 1 Echocardiographic Measures of RV Size and Function
Systolic size and function
Indexed end-systolic volume
RV ejection fraction
RV % fractional area change
Tissue Doppler tricuspid peak annular systolic velocity
Tissue Doppler tricuspid annular isovolumic acceleration
Diastolic size and function
Indexed end-diastolic volume
Indexed end-diastolic area
Peak tricuspid E and A inﬂow velocity
Tricuspid E/A ratio
Tricuspid tissue Doppler E’ and A’ velocity
E/E’ ratio
Presence of pulmonary vein reversal at atrial systole
Global function
Myocardial performance index
RV ¼ right ventricle/ventricular.
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2028examined with histograms. Echocardiographic indices
were compared between shunt groups at the pre-
Fontan study. In addition, we performed paired com-
parisons of changes in these indices from 14 months of
age (which marked the end of the SVR study visit from
previously published data) (4) and the pre-Fontan
study between shunt groups when a protocol echo-
cardiogram was available at both time periods. Con-
tinuous measures were compared between assigned
shunt types with either Student or Welch’s t test or a
Wilcoxon rank sum test as appropriate. Categorical
measures were compared between shunt types with a
Fisher exact test; ordinal measures were compared
with a Fisher exact test and the Mantel-Haenszel
test for trend. For paired analysis between values
obtained at 14 months and the pre-Fontan study, the
mean and standard deviation of the change over
time in each of the echocardiographic measures
were compared between shunt groups using a Stu-
dent t test. Finally, echocardiographic indices ob-
tained at 14 months were explored to assess whether
they predicted transplant-free survival from the timeTABLE 2 Echocardiographic Measures of
Valve and Aortic Size and Function
Tricuspid valve
Indexed valve area
Severity of regurgitation
Neo-aortic valve
Indexed valve area
Severity of regurgitation
Aortic size and patency
Ascending aortic diameter
Peak descending aortic velocityof that study to Fontan surgery. The hazard ratios for
death or heart transplant after the 14-month echo-
cardiogram were assessed as a function of the echo-
cardiographic measurement using Cox proportional
hazards regression. The hazard ratio measures the
association of the echocardiogram parameter with
transplant-free survival, and the p value tests
whether the hazard ratio is signiﬁcantly different
from 1 (no effect). Subjects who did not die or receive
a heart transplant between the date of the 14-month
echocardiogram and the date of Fontan surgery
were censored at the time of their Fontan procedure.
The p values were considered signiﬁcant at <0.05.
Analyses were performed in SAS version 9.3 (SAS
Institute, Cary, North Carolina). To adjust for the ef-
fect of somatic growth and age on the linear, area, and
volumetric dimensions of cardiac structures and
Doppler ﬂow patterns, z scores were used when
normative data were available (8). The dimensions of
the neo-aortic valve annulus were expressed as z
scores using normal values for the dimensions of the
native aortic valve in a normal population. These z
scores are calculated with respect to body surface
area (BSA), with the power of BSA determined by
prior work examining linearity between echo mea-
sures and various functions of BSA (9).
All echocardiographic measures were performed by
a single dedicated pediatric echocardiography tech-
nician and all measures were conﬁrmed by a single
experienced pediatric echocardiographer. To access
reproducibility of echocardiogram measurements,
approximately 5% of the echocardiograms at each
time point were randomly selected to be read blindly
a second time by the same echocardiographer. The
intrarater intraclass correlations and percent agree-
ment for continuous and dichotomous variables,
respectively, were calculated. Agreement was good
(>80%) for most variables; RV volume assessment
had more variance, but this did not affect the con-
sistency of right ventricular ejection fraction (RVEF)
estimates (86% agreement).
RESULTS
Of the 262 SVR survivors who had echocardiographic
studies submitted within 6 months of planned Fon-
tan, 258 (98.5%; 125 MBTS and 133 RVPAS) were
acceptable for core-lab analysis. The mean age at the
time of the pre-Fontan echocardiogram was 33.6  9.6
months (median 32.7 months; range 13.6 to 65.9
months). Among the 258 subjects, 240 (93%; 114
MBTS and 126 RVPAS) also had undergone a 14-month
protocol echocardiogram at a mean of 14.1  1.2
months (median 14.1 months, range 11 to 20.9
TABLE 3 Summary Statistics for Pre-Fontan Echocardiographic Measures
by Initial Shunt Group
MBTS RVPAS p Value
RV systolic size and function
End-systolic volume, ml/BSA1.3 68 51.1  15.7 79 54  17.9 0.30
End-systolic area, cm2/BSA0.8 102 16.4  4.2 112 17  4.2 0.32
Ejection fraction, % 68 45  6 79 42  7 0.007*
Fractional area change, % 102 31  6 112 31  6 0.36
Peak systolic velocity, cm/s 75 5.68  1.48 88 5.7  1.6 0.93
Isovolumic contraction acceleration, cm/s2 43 33.1  8.74 62 35.1  11.9 0.34
RV diastolic size and function
End-diastolic volume, ml/BSA1.3 68 92  24.5 79 92.1  26.3 0.98
End-diastolic area, cm2/BSA0.8 102 23.8  5.1 112 24.4  5.3 0.38
Tricuspid valve peak early velocity, m/s 108 0.79  0.23 109 0.76  0.20 0.27
Tricuspid valve peak atrial velocity, m/s 82 0.70  0.20 84 0.66  0.21 0.30
E/A ratio 82 1.09  0.32 84 1.16  0.32 0.17
Peak early annular diastolic velocity, cm/s 75 8.64  2.92 88 9.10  2.69 0.30
Peak atrial annular diastolic velocity, cm/s 63 6.98  2.49 68 6.80  1.67 0.64
E/E’ ratio 71 10.36  5.47 83 8.85  3.23 0.04*
Flow reversal during atrial systole 77 98 0.24
Yes 5 (6.5) 2 (2.0)
No 72 (93.5) 96 (98.0)
RV global function
MPI, inﬂow Doppler calculation 95 0.45  0.17 92 0.45  0.19 0.93
MPI, DTI calculation 46 0.63  0.27 58 0.59  0.19 0.46
Neo-aortic valve size and function
Neo-aortic annular area/BSA 108 3.85  0.87 111 3.69  1.08 0.22
Neo-aortic annular area, z score 108 5.59  2.54 111 5.12  3.12 0.22
Severity of neo-aortic valve regurgitation 121 130 0.73
None 74 (61.2) 78 (60.0)
Mild 44 (36.4) 46 (35.4)
Moderate 3 (2.5) 6 (4.6)
Severe 0 (0.0) 0 (0.0)
$Moderate neo-aortic valve regurgitation 121 130 0.50
Yes 3 (2.5) 6 (4.6)
No 118 (97.5) 124 (95.4)
Tricuspid valve size and function
Tricuspid indexed annular area/BSA 113 5.51  1.83 120 5.71  1.62 0.37
Tricuspid indexed annular area
for BSA, z score
113 1.87  2.23 120 2.11  1.96 0.38
Severity of tricuspid valve regurgitation 121 131 0.79
None 14 (11.6) 19 (14.5)
Mild 84 (69.4) 91 (69.5)
Moderate 17 (14.0) 17 (13.0)
Severe 6 (5.0) 4 (3.1)
Multiple 0 (0.0) 0 (0.0)
$Moderate tricuspid valve regurgitation 121 131 0.62
Yes 23 (19.0) 21 (16.0)
No 98 (81.0) 110 (84.0)
Aortic size and patency
Ascending aortic maximal diameter, cm 102 1.95  0.38 111 1.90  0.40 0.37
Ascending aortic maximal diameter
for BSA, z score
102 3.43  2.32 111 3.10  2.41 0.31
Distal arch to descending aorta CWD
peak velocity, m/s
91 1.67  0.51 96 1.81  0.58 0.08
Values are n, mean  SD, or n (%). *p values <0.05 were considered signiﬁcant.
BSA ¼ body surface area; CWD ¼ continuous wave Doppler; DTI ¼ Doppler tissue imaging; MBTS ¼ modiﬁed
Blalock-Taussig shunt; MPI ¼ myocardial performance index; RV ¼ right ventricle/ventricular; RVPAS ¼ right
ventricle-to-pulmonary artery shunt.
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2029months); of the remaining 18 subjects, 16 had no 14-
month echocardiogram and 2 had undergone their
Fontan at the time of or before the 14-month study.
For the 240 subjects with paired echocardiograms,
the mean duration between the 14-month echocar-
diogram and the pre-Fontan echocardiogram was 19.6
 9.5 months (range: 1.5 to 51.9 months).
ECHOCARDIOGRAPHIC ASSESSMENT. RV systo l i c
s i ze and funct ion . At the pre-Fontan echocardio-
gram, RVEF was signiﬁcantly higher in the MBTS
subjects compared with RVPAS (45  6% vs. 42  7%;
p ¼ 0.007). All other values at this time point were
similar between shunt types including RV indexed
systolic volume, indexed systolic area, percent frac-
tional area change, peak tricuspid annular systolic
velocity, and isovolumic acceleration (Table 3).
In comparing the 14-month and pre-Fontan
studies, we found no signiﬁcant change in RVEF or
systolic volume in the MBTS group. However, RV
indexed end-systolic area increased and fractional
area change decreased between the 2 time periods.
All other systolic indices were similar (Table 4). In
the RVPAS group, the RV indexed end-systolic area
and end-systolic volume both increased while frac-
tional area change and ejection fraction (44  7%
vs. 41  7%; p ¼ 0.004) both decreased over time
(Table 5, Figure 1). This interval change in RVEF
differed signiﬁcantly between groups (–3.24 for the
RVPAS vs. 0.99 for the MBTS; p ¼ 0.009). No other
signiﬁcant changes in systolic indices were identiﬁed
from 14 months to the pre-Fontan study for the
RVPAS group.
RV diastol i c s i ze and funct ion . Diastolic indices,
including RV indexed end-diastolic volume, indexed
end-diastolic area, tricuspid peak E and A velocities
and E/A ratio, tricuspid annular E’ and A’ velocities,
E/E’ ratio, and presence of pulmonary vein ﬂow
reversal during atrial systole were similar between
shunt groups at the pre-Fontan study (Table 3). In
addition, the presence of pulmonary vein reversal of
ﬂow with atrial systole was rarely identiﬁed in either
group (6.5% in MBTS, 2% in RVPAS; p ¼ 0.24). When
compared with measures obtained at 14 months,
there was no signiﬁcant change in diastolic indices
over time for the MBTS group (Table 4). In the RVPAS
group, tricuspid peak E and A velocities decreased
and the tricuspid annular E’ velocity increased from
14 months to the pre-Fontan study, which resulted in
a signiﬁcantly decreased E/E’ ratio at the pre-Fontan
study, bringing this measure into the normal range
(E/E’ ratio for age z score 3.0  2.6 at 14 months vs.
1.7  2.0 pre-Fontan). All other diastolic indices were
TABLE 4 Summary Statistics for 14-Month and Pre-Fontan Echocardiographic Measures
(MBTS Group)
14 Months Pre-Fontan p Value
RV systolic size and function
End-systolic volume, ml/BSA1.3 56 49.39  16.62 51.23  15.45 0.35
End-systolic area, cm2/BSA0.8 93 15.52  3.54 16.45  3.37 0.01*
Ejection fraction, % 56 44  8 45  6 0.40
Fractional area change, % 93 33  7 31  5 0.02*
Peak systolic velocity, cm/s 70 5.56  1.38 5.67  1.51 0.51
Isovolumic contraction acceleration, cm/s2 29 35.34  9.94 31.90  8.14 0.17
RV diastolic size and function
End-diastolic volume, ml/BSA1.3 56 87.07  23.41 92.17  24.60 0.07
End diastolic area, cm2/BSA0.8 93 23.13  4.35 23.94  4.43 0.09
Transverse valve peak early velocity, m/s 95 0.85  0.24 0.80  0.23 0.05*
Transverse valve peak atrial velocity, m/s 48 0.74  0.21 0.69  0.18 0.21
E/A ratio 48 1.11  0.37 1.17  0.34 0.36
Peak early diastolic velocity, cm/s 70 8.89  3.59 8.57  2.99 0.47
Peak atrial diastolic velocity, cm/s 35 7.01  2.25 7.35  2.81 0.43
E/E’ ratio 65 11.42  5.12 10.67  5.60 0.23
Flow reversal during atrial systole 69 >0.99
Yes 5 (7.2) 4 (5.8)
No 64 (92.8) 65 (94.2)
RV global function
MPI, inﬂow Doppler calculation 84 0.44  0.16 0.45  0.17 0.58
MPI, DTI calculation 30 0.57  0.20 0.62  0.28 0.37
Valvular size and function
Neo-aortic annular area/BSA 96 4.35  1.05 3.89  0.83 <0.001*
Neo-aortic annular area for BSA, z score 96 6.80  2.94 5.70  2.44 <0.001*
Severity of neo-aortic valve regurgitation 110 <0.001*
None 45 (40.9) 69 (62.7)
Mild 64 (58.2) 39 (35.5)
Moderate 1 (0.9) 2 (1.8)
Severe 0 (0.0) 0 (0.0)
$ Moderate neo-aortic valve regurgitation 110 >0.99
Yes 1 (0.9) 2 (1.8)
No 109 (99.1) 108 (98.2)
Tricuspid valve size and function
Tricuspid indexed annular area/BSA 105 6.16  1.88 5.59  1.84 <0.001*
Tricuspid indexed annular area
for BSA, z score
105 2.61  2.24 1.96  2.24 0.002*
Severity of tricuspid valve regurgitation 111 0.78
None 17 (15.3) 12 (10.8)
Mild 72 (64.9) 78 (70.3)
Moderate 16 (14.4) 15 (13.5)
Severe 6 (5.4) 6 (5.4)
Multiple 0 (0.0) 0 (0.0)
$Moderate tricuspid valve regurgitation 111 0.99
Yes 22 (19.8) 21 (18.9)
No 89 (80.2) 90 (81.1)
Aortic size and patency
Ascending aortic maximal diameter, cm Not collected at 14 months
Ascending aortic maximal diameter
for BSA, z score
Not collected at 14 months
Distal arch to descending aorta CWD
peak velocity, m/s
71 1.67  0.55 1.72  0.52 0.25
Values are n, mean  SD, or n (%). *p values <0.05 were considered signiﬁcant.
Abbreviations as in Table 3.
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2030stable between the 2 intervals for the RVPAS group
(Table 5).
RV globa l funct ion . The myocardial performance
index, as assessed by both blood ﬂow Doppler and
annular Doppler tissue imaging, was not signiﬁcantly
different between the shunt groups at the pre-Fontan
study (Table 3). Additionally, we found no signiﬁcant
change in the index as calculated by either method
from 14 months to the pre-Fontan study for either
group (Tables 4 and 5).
Neo-aort i c va lve s ize and funct ion . Indexed neo-
aortic annular areas were similar in both shunt groups
at the pre-Fontan study with marked neo-aortic
annular dilation, as evidenced by mean z scores of
5.6  2.5 for MBTS and 5.1  3.1 for RVPAS (p ¼ 0.22)
(Table 3). Both shunt groups showed a signiﬁcant
decrease in indexed neo-aortic valve size from the 14-
month to the pre-Fontan study, however, with an
average change in z score of –1.1 for the MBTS and –1.3
for the RVPAS (Figure 2). This change over time was
not signiﬁcantly different between the shunt groups.
The degree of neo-aortic regurgitation was similar in
the 2 groups and did not vary signiﬁcantly between
time points. At the pre-Fontan study, 2.5% of the
MBTS and 4.6% of the RVPAS cohort (p ¼ 0.73) had
moderate regurgitation and no subject had severe
regurgitation.
TV s ize and funct ion . Indexed tricuspid annular
area and z score were similar in both groups at the
pre-Fontan study, with a mean z score of 1.9  2.2 for
MBTS and 2.1  2.0 for RVPAS (p ¼ 0.38) (Table 3).
Both groups demonstrated a signiﬁcant decrease in
indexed TV size from the 14-month to the pre-Fontan
study. The degree of change over time was similar for
both groups, with an average change in z score of –0.7
for the MBTS and –0.9 for the RVPAS (Figure 3). The
degree of tricuspid regurgitation was comparable in
the 2 groups, with 19% of the MBTS and 16% of the
RVPAS cohort (p ¼ 0.62) having moderate or severe
regurgitation at the pre-Fontan study. The percent-
age of subjects with moderate or greater tricuspid
regurgitation was stable when compared with the
14-month assessment; it was present in <20% in both
groups at both intervals.
Aort ic s ize and patency . The ascending aortic
diameter was similar in both shunt groups at the pre-
Fontan study with moderate ascending aortic dila-
tion, as evidenced by mean z scores of 3.4  2.3 for
MBTS and 3.1  2.4 for RVPAS (p ¼ 0.31) (Table 3). As
the ascending aorta was not quantiﬁed at the 14-
month study, information about change over time
was unavailable. We saw similarities in peak velocity
TABLE 5 Summary Statistics for 14-Month and Pre-Fontan Echocardiographic Measures
(RVPAS Group)
14 Months Pre-Fontan p Value
RV systolic size and function
End systolic volume, ml/BSA1.3 58 49.11  14.47 55.00  17.84 0.004*
End-systolic area, cm2/BSA0.8 98 15.96  3.64 17.09  3.96 0.004*
Ejection fraction, % 58 44  7 41  7 0.004*
Fractional area change, % 98 33  6 31  6 <0.001*
Peak systolic velocity, cm/s 72 5.06  1.40 5.59  1.60 0.02*
Isovolumic contraction acceleration, cm/s2 37 35.86  11.90 37.31  10.11 0.50
RV diastolic size and function
End-diastolic volume, ml/BSA1.3 58 87.73  23.58 92.59  25.82 0.09
End-diastolic area, cm2/BSA0.8 98 23.92  4.97 24.53  4.95 0.22
Transverse valve peak early velocity, m/s 98 0.81  0.23 0.76  0.20 0.02*
Transverse valve peak atrial velocity, m/s 55 0.70  0.22 0.65  0.22 0.01
E/A ratio 55 1.11  0.35 1.17  0.35 0.23
Peak early diastolic velocity, cm/s 72 7.79  2.80 9.09  2.76 <0.001*
Peak atrial diastolic velocity, cm/s 40 6.53  2.03 6.89  1.71 0.30
E/E’ ratio 67 11.28  4.12 8.75  3.16 <0.001*
Flow reversal during atrial systole 82 0.44
Yes 5 (6.1) 2 (2.4)
No 77 (93.9) 80 (97.6)
RV global function
MPI, inﬂow Doppler calculation 79 0.42  0.14 0.46  0.19 0.07
MPI, DTI calculation 33 0.59  0.17 0.58  0.11 0.79
Valvular size and function
Neo-aortic annular area/BSA 95 4.20  1.15 3.67  1.01 <0.001*
Neo-aortic annular area for BSA, z score 95 6.37  3.21 5.07  2.91 <0.001*
Severity of neo-aortic valve regurgitation 121 0.97
None 70 (57.9) 72 (59.5)
Mild 46 (38.0) 44 (36.4)
Moderate 5 (4.1) 5 (4.1)
Severe 0 (0.0) 0 (0.0)
$Moderate neo-aortic valve regurgitation 121 >0.99
Yes 5 (4.1) 5 (4.1)
No 116 (95.9) 116 (95.9)
Tricuspid valve size and function
Tricuspid indexed annular area/BSA 110 6.47  2.11 5.69  1.63 <0.001*
Tricuspid indexed annular area
for BSA, z score
110 2.97  2.51 2.09  1.98 <0.001*
Severity of tricuspid valve regurgitation 122 0.88
None 21 (17.2) 17 (13.9)
Mild 81 (66.4) 84 (68.9)
Moderate 15 (12.3) 17 (13.9)
Severe 5 (4.1) 4 (3.3)
Multiple 0 (0.0) 0 (0.0)
$Moderate tricuspid valve regurgitation 122 >0.99
Yes 20 (16.4) 21 (17.2)
No 102 (83.6) 101 (82.8)
Aortic size and patency
Ascending aortic maximal diameter, cm Not collected at 14 months
Ascending aortic maximal diameter
for BSA, z score
Not collected at 14 months
Distal arch to descending aorta CWD
peak velocity, m/s
75 1.80  0.66 1.81  0.63 0.93
Values are n, mean  SD, or n (%). *p values <0.05 were considered signiﬁcant.
Abbreviations as in Table 3.
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2031through the distal aortic arch between the shunt
groups at the pre-Fontan study (1.7  0.5 for MBTS vs.
1.8  0.6 m/s for RVPAS; p ¼ 0.08). The peak velocity
was also stable when compared with the 14-month
assessment, with average peak velocities <2 m/s for
both groups at both intervals (Tables 4 and 5).
TRANSPLANT-FREE SURVIVAL TO FONTAN. Eigh-
teen subjects died or required heart transplantation
from the 14-month echocardiographic study to the
Fontan procedure. In univariate analyses, a larger RV
indexed end-systolic volume and area, lower RVEF,
larger RV indexed diastolic volume and area, higher
peak early diastolic tricuspid ﬁlling velocity, higher
myocardial performance index (MPI), larger indexed
tricuspid indexed annular area and z score for BSA,
and at least moderate TV regurgitation were associ-
ated with an increased risk of transplant or death
between the 14-month echocardiogram to Fontan
palliation (Table 6). Neo-aortic valve size, degree of
neo-aortic regurgitation, and aortic arch gradient at
14 months were not associated with transplant-free
survival to Fontan.
DISCUSSION
The SVR trial provides a unique opportunity for lon-
gitudinal assessment of a large, high-risk cohort of
children born with single right ventricle anomalies as
they progress through staged surgical palliation. In
previous work, initial shunt type used with the Nor-
wood procedure was found to inﬂuence transplant-
free survival at 1 year, with lower mortality in those
subjects who received a RVPAS compared with a
MBTS (3). However, this survival beneﬁt appears to
dissipate with time after the ﬁrst year, so the best
surgical strategy remains in question. In the current
manuscript, we describe changes in echocardio-
graphic indices of RV, neo-aortic, and TV size and
function from completion of the initial trial (14
months, which marked the end of the primary SVR
study visit) until subsequent Fontan surgery was
performed.
Preservation of single RV function from the time of
the Norwood onward is paramount for children un-
dergoing staged palliation as the resultant physiology
depends on well-maintained RV function to avoid
chronic cardiovascular morbidities including heart
failure, frequent hospitalizations, arrhythmias, and
transplant, as well as early mortality. Here, we found
that initial shunt type appears to inﬂuence RV
remodeling during the second and third years of life
before Fontan surgery with deterioration in RVEF in
14 Months Pre-Fontan
MBTS RVPAS RVPASMBTS
RVEF
p=0.004
55
50
45
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35
30
FIGURE 1 Comparison of RVEF Between the MBTS and RVPAS
Groups at the 14-Month and Pre-Fontan Echocardiograms
There was no signiﬁcant change in right ventricular ejection
fraction (RVEF) in the modiﬁed Blalock-Taussig shunt (MBTS)
group, whereas the right ventricle to pulmonary artery shunt
(RVPAS) group had signiﬁcantly decreased ejection fraction
compared with the 14-month study (bracket). *Pre-Fontan
value is signiﬁcantly different than the bracketed value at
the 14-month study.
6
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14 Months Pre-Fontan
MBTS RVPAS RVPASMBTS
Tricuspid indexed annular z-score
p=0.002 p<0.001
FIGURE 3 Comparison of Indexed Tricuspid Annular z Scores
Between the MBTS and RVPAS Groups at the 14-Month
and Pre-Fontan Echocardiograms
Indexed tricuspid annular area and z score were similar in both
shunt groups at the pre-Fontan study, with a signiﬁcant decrease
in both groups from the 14-month study (brackets). Abbrevia-
tions as in Figure 1. *Pre-Fontan value is signiﬁcantly different
than the bracketed value at the 14-month study.
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2032those with an RVPAS (Central Illustration). This
change is associated with poorer transplant-free sur-
vival during the same time period for subjects with an
RVPAS (10), raising concerns that this surgical strat-
egy may result in progressive deleterious effects on
RV systolic function that could have important14 Months Pre-Fontan
MBTS RVPAS RVPASMBTS
Neo-aortic indexed annular z-score
p<0.001 p<0.001
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FIGURE 2 Comparison of Indexed Neo-Aortic Annular z Scores
Between the MBTS and RVPAS Groups at the 14-Month
and Pre-Fontan Echocardiograms
Indexed neo-aortic annular z scores were similar in both groups at
the pre-Fontan study, with marked neo-aortic annular dilation
and with a signiﬁcant decrease in valve size for both groups from
the 14-month study (brackets). Abbreviations as in Figure 1. *Pre-
Fontan value is signiﬁcantly different than the bracketed value at
the 14-month study.implications for long-term morbidity and mortality.
Although previous single-center studies have also
shown improved early outcomes with the RVPAS
compared with the MBTS (11–14), concerns about
poorer qualitative (15,16) and quantitative (17) RV
systolic function before and after the ﬁnal stage
Fontan operation have been described in patients
who had the RVPAS. It has been hypothesized that
the ventriculotomy required for the RVPAS may cause
myocardial injury and/or scar with aneurysm forma-
tion, and that this injury may ultimately affect ven-
tricular performance (18). If true, it is possible that
the effects of this early myocardial injury take time to
manifest in a way that echocardiography can mea-
sure. No difference was detected in RV fractional area
change, but this method does not evaluate the
outﬂow tract, which could potentially be the area
most affected by the ventriculotomy scar. RVEF, as
calculated here by the biplane pyramidal method (19),
is likely a more sensitive tool for RV systolic function
in this cohort.
Review of other echocardiographic indices that
characterize ventricular function in this cohort did
not provide a clear picture of RV failure in the RVPAS
survivors before Fontan, which suggests that con-
clusions about the shunt-inﬂuenced health of the RV
may require additional longitudinal follow-up.
Indexed RV end-diastolic volumes and areas were
stable and did not show the expected progressive
chamber dilation of a failing ventricular pump in
either shunt group between 14 months and the pre-
Fontan studies. Global indices of function were also
TABLE 6 Univariate Analysis of 14-Month Echocardiographic Indices as Predictors of Transplant-Free Survival From the
Time of Study to Fontan Surgery
Transplant-Free Survivors Transplanted or Died Hazard Ratio p Value
RV systolic size and function
End-systolic volume, ml/BSA1.3 221 49.88  16.74 12 99.61  53.29 1.05 <0.001*
End-systolic area, cm2/BSA0.8 284 15.82  4.07 17 20.98  8.09 1.16 <0.001*
Ejection fraction, % 221 43  7 12 34  9 0.85 <0.001*
Area fraction, % 284 33  7 17 26  8 0.89 <0.001*
Peak systolic velocity, cm/s 291 5.33  1.44 17 5.81  1.23 1.24 0.18
Isovolumic contraction acceleration, cm/s2 156 35.24  11.57 8 32.50  8.80 0.98 0.58
RV diastolic size and function
End-diastolic volume, ml/BSA1.3 221 87.54  24.64 12 144.88  57.24 1.05 <0.001*
End-diastolic area, cm2/BSA0.8 284 23.50  5.02 17 28.16  8.52 1.15 <0.001*
Transverse valve peak early velocity, m/s 300 0.86  0.25 17 0.96  0.24 4.46 0.08
Transverse valve peak atrial velocity, m/s 172 0.72  0.20 3 0.67  0.31 0.23 0.62
E/A ratio 172 1.09  0.39 3 1.21  0.34 1.78 0.54
Peak early diastolic velocity, cm/s 294 8.56  3.60 17 11.41  4.57 1.16 0.002*
Peak atrial diastolic velocity, cm/s 168 6.82  2.24 5 7.50  1.93 1.14 0.50
E/E’ ratio 288 11.32  4.82 16 9.81  5.43 0.93 0.22
Flow reversal during atrial systole 291 18 (6.2%) 17 3 (17.6%) 0.29 0.05
RV global function
MPI, inﬂow Doppler calculation 281 43.47  16.33 15 55.53  22.27 1.03 0.006*
MPI DTI calculation 169 0.60  0.20 5 0.63  0.23 2.42 0.68
Valvular size and function
Neo-aortic annular area/BSA 287 4.24  1.09 18 4.30  1.10 1.05 0.82
Neo-aortic annular area for BSA, z score 287 6.50  3.06 18 6.65  3.08 1.02 0.83
At least moderate neo-aortic valve regurgitation 312 7 (2.2) 18 1 (5.6) 0.34 0.29
Tricuspid valve size and function
Tricuspid indexed annular area/BSA 306 6.36  2.00 18 7.53  2.51 1.29 0.02*
Tricuspid indexed annular area for BSA, z score 306 2.85  2.38 18 4.25  3.02 1.24 0.02*
At least moderate tricuspid valve regurgitation 312 65 (20.8) 18 8 (44.4) 0.34 0.02*
Neo-aortic size and patency
Distal arch to descending aorta CWD
peak velocity, m/s
246 1.67  0.55 15 1.73  0.56 1.25 0.63
Values are n, mean  SD, or n (%). *p values <0.05 were considered signiﬁcant.
Abbreviations as in Table 3.
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2033remarkably stable and similar for both shunt groups
over time as assessed by the myocardial performance
index, with the RV MPI (as calculated by inﬂow
Doppler) well below (i.e., much better than) previ-
ously published values for children with single
ventricle anomalies after staged palliation using the
same MPI technique (20). Additionally, RV diastolic
indices, which typically show the earliest pathologic
changes with progressive ventricular dysfunction, are
also stable with little evidence of progressive
restrictive disease in either group as evidenced by the
absence of subjects who exhibited late diastolic pul-
monary venous reversal of ﬂow. In fact, diastolic
function appears to improve over time in the RVPAS
survivors from the 14-month to the pre-Fontan eval-
uation, with a signiﬁcantly decreased tricuspid E/E’
ratio that falls within 2 standard deviations of age-
matched normal controls.Neo-aortic and TV size and function also exhibited
reassuring trends from 14 months to the pre-Fontan
echocardiogram. Although the neo-aortic annulus
remained markedly dilated compared with normative
controls at both intervals, there was a signiﬁcant
decrease in indexed annular size and z score over
time in both shunt groups. Despite the signiﬁcant
neo-aortic annular and ascending aortic dilation,
more than mild valve regurgitation was rare (<5%)
and similar at both intervals for the 2 shunt groups.
Neo-aortic valve size and integrity will be important
to track in this cohort over time, given reports of
signiﬁcant neo-aortic root dilation and neo-aortic
valve regurgitation later in childhood after Norwood
palliation with MBTS (21). In our cohort, it is similarly
encouraging that indexed tricuspid annular size also
decreased at the pre-Fontan study compared with the
14-month assessment in both shunt groups, nearly
SINGLE RV ANOMALY
SVR cohort randomized to MBTS vs RVPAS
SIMILAR:
RV size
RV diastolic function
RV global function
Neo-aortic size and valve function
Tricuspid valve size and function
WORSE:
RV ejection fraction
Comparison of echo measures 
from 14 months to pre-Fontan
MBTS RVPAS
Frommelt, P.C., et al., J Am Coll Cardiol. 2014; 64(19):2026–35.
CENTRAL ILLUSTRATION Flow Diagram of the Results of the SVR Extension Trial
At 14 months, patients in the single ventricle reconstruction (SVR) trial showed no dif-
ferences in right ventricular (RV) function whether they had received a right ventricle to
pulmonary artery shunt (RVPAS) or modiﬁed Blalock-Taussig shunt (MBTS), but longer-
term results in the SVR extension trial demonstrated greater RV ejection fraction deteri-
oration after RVPAS. Encouragingly, other indices of RV function remained stable before
Fontan regardless of shunt type. echo = echocardiographic.
Frommelt et al. J A C C V O L . 6 4 , N O . 1 9 , 2 0 1 4
Shunt Type and Pre-Fontan RV Remodeling N O V E M B E R 1 1 , 2 0 1 4 : 2 0 2 6 – 3 5
2034normalizing in size with z scores approximating 2.
The incidence of moderate or greater tricuspid
regurgitation was stable (<20% at both intervals for
both groups), a ﬁnding that differs from a recently
published report that identiﬁed worse TV function
in the MBTS patients after Fontan (22).
After their ﬁrst year, children with single RV
anomalies remain at risk for death or transplant
before Fontan surgery. Not surprisingly, transplant-
free survival to Fontan was associated with signi-
ﬁcantly smaller RV indexed end-diastolic and
end-systolic volumes and areas, higher RV percent
fractional area change and RVEF, lower myocardial
performance index, smaller TV indexed annular area,
and a lower incidence of moderate or worse TVregurgitation at 14 months. This suggests that pa-
tients with signiﬁcantly larger RV volumes, decreased
RV systolic and global functional indices, TV annular
dilation, and signiﬁcant TV regurgitation warrant
closer surveillance.
STUDY LIMITATIONS. Unlike for the left ventricle, 2D
echocardiographic tools used to assess RV volume
and systolic function remain limited due to the
chamber’s complex geometry. Analysis of regional RV
wall motion was not performed as part of this proto-
col, so the impact of focal scarring/dyskinesis was
not speciﬁcally assessed. Careful training in protocol
image acquisition was provided and reinforced at all
sites with regular quality assurance feedback from the
core lab to optimize appropriate image capture;
consequently, >98% of the submitted studies were
found to be acceptable in providing images that
allowed data extraction. However, while data ex-
traction was possible in nearly all studies, not all
measurements were achievable in the majority of
studies because of incomplete or inadequate image
acquisition. The impact of this limitation in the
characterization of RV function for this cohort is
unclear but emphasizes the challenge of multi-
institutional echocardiographic trials that require
extensive data acquisition, particularly when
obtaining those data from young children with com-
plex heart disease.
CONCLUSIONS
Initial shunt type used with the Norwood procedure
may inﬂuence RV remodeling during the second and
third years of life before Fontan surgery in survivors
with single RV anomalies, as evidenced by decreased
RVEF after the RVPAS that is not seen after MBTS.
Other echocardiographic measures of RV function,
however, appear to remain stable in both shunt
groups. In addition, neo-aortic and TV size decrease
in both shunt groups over time, and both valves
continue to function well for most survivors without
progressive regurgitation before the Fontan. Factors
associated with poorer transplant-free survival to the
Fontan operation included echocardiographic evi-
dence of markedly enlarged RV volumes, severely
abnormal RV systolic and global indices of function,
signiﬁcant tricuspid annular dilation, and at least
moderate tricuspid regurgitation at 14 months.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Initial
shunt type used for the Norwood procedure may inﬂu-
ence RV remodeling during the second and third years
of life before Fontan surgery in survivors with single
RV anomalies, as evidenced by decreased RVEF after
the RVPAS procedure that is not seen in those after use
of the MBTS. Other echocardiographic measures of RV
and valve function, however, appear to remain stable in
both shunt groups.
COMPETENCY IN PATIENT CARE: The best choice
of initial shunt type in infants requiring the Norwood
procedure for single RV anomalies remains unclear on the
basis of current data from the SVR trial.
TRANSLATIONAL OUTLOOK: Longitudinal follow-up
of the SVR trial cohort is ongoing and will likely provide
further insights into the long-term effect of initial shunt
type on clinical outcome and echocardiographic indices of
cardiac size and function.
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